2445: Poolbeg’s Big Biotech Moment? First Patient Dosed Ahead of Key POLB 001 Data

from The Vox Markets Podcast · host Vox Markets Podcast

Watch on YouTubePoolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL clinical trial, marking the start of a key execution phase for its CRS prevention programme. With UCLH activated, further sites expected, interim data targeted for summer 2026 and partnering discussions ongoing, investors will be watching whether clinical progress can validate the programme’s claimed commercial potential.

Episode metadata supplied by the publisher feed · Published Jul 13, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

2445: Poolbeg’s Big Biotech Moment? First Patient Dosed Ahead of Key POLB 001 Data

0:00 8:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Vox Markets Podcast?

This episode is 8 minutes long.

When was this The Vox Markets Podcast episode published?

This episode was published on July 13, 2026.

Can I download this The Vox Markets Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!